Bernard D. D. S.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase 1a/1b Open-Label Study of IGM-8444 Monotherapy and Combination Therapy in Relapsed, Refractory, or Newly Diagnosed Colorectal Cancer
- Phase I Clinical Trial of TOS-358 in Adult Patients with Advanced Solid Tumors: Colorectal, Cervical, Endometrial, Gastric, Urothelial, Breast, Head and Neck, Ovarian, and NSCLC.
- Evaluation of Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Advanced Unresectable or Metastatic NSCLC, BC, PDAC, and CRC.
Data & Insights
Has run more than one trial at 158 of 268 partner sites.
Specializations
Thoracic and upper gastrointestinal oncology
Clinical research activity is centered on non-small cell lung cancer, small cell lung cancer, head and neck squamous cell carcinoma, esophageal cancer, gastric cancer, and biliary tract cancer, with additional involvement in mesothelioma and pancreatic adenocarcinoma.
- Non-small cell lung cancer
- Small cell lung cancer
- Head and neck squamous cell carcinoma
- Gastric and biliary tract malignancies
The portfolio includes advanced and metastatic disease settings, with emphasis on targeted therapy and immunotherapy strategies in solid tumors.
Breast, gynecologic, and urothelial cancers
Work in this area spans breast cancer, including hormone receptor-positive, HER2-negative, HER2-positive, and triple-negative breast cancer, together with endometrial cancer, ovarian cancer, cervical cancer, and urothelial carcinoma.
- Breast cancer subtypes
- Endometrial and ovarian cancer
- Cervical cancer
- Urothelial carcinoma
Therapeutic interest includes biomarker-defined disease, antibody-drug conjugates, and endocrine-based approaches in recurrent or metastatic cancers.
Hematologic malignancies and cellular therapy
Research involvement covers acute myeloid leukemia, myelodysplastic syndromes, chronic lymphocytic leukemia, multiple myeloma, and a broad spectrum of B-cell and T-cell lymphomas.
- Acute myeloid leukemia
- Multiple myeloma
- Diffuse large B-cell lymphoma
- Chronic lymphocytic leukemia
This includes interest in CAR T-cell therapy, bispecific antibodies, and other novel hematologic cancer treatments.
Targeted treatments for genomically defined solid tumors
The investigator is active in trials for EGFR-mutated, ALK-positive, ROS1-positive, RET-altered, KRAS-mutant, BRAF-mutant, and HER2-altered cancers, as well as IDH-mutant glioma and chondrosarcoma.
- Biomarker-selected lung cancer
- KRAS-driven solid tumors
- HER2-altered malignancies
- IDH-mutant and BRAF-mutant tumors
Key interests include precision oncology for advanced solid tumors, with a focus on molecularly selected treatment options.
Immune-mediated, renal, and supportive care conditions
Beyond oncology, clinical activity extends to asthma, atopic dermatitis, psoriasis, inflammatory bowel disease, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, and autosomal dominant polycystic kidney disease.
- Asthma and allergic disease
- Autoimmune skin and systemic disease
- Inflammatory bowel disease
- Kidney disease and proteinuric disorders
Additional interest includes cardiovascular disease, neurology, and infectious disease indications linked to complex supportive and comorbidity management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.